The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab ...

For patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, adjuvant trastuzumab ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

Updated results from the KATHERINE trial showed that adjuvant T-DM1 provided a significant improvement in overall survival and no evidence of long-term safety issues.

In the DESTINY-Breast03 trial, Enhertu reduced the risk of disease progression or death by 72% versus Roche's Kadcyla (trastuzumab emtansine), which has been a go-to second-line therapy for HER2 ...

They include: Ado-trastuzumab emtansine (Kadcyla): Oncologists use Kadcyla in the adjuvant setting after surgery if there is residual disease in the breast and if a person has had neoadjuvant ...

The serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Ketoconazole.

Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly assigned to receive either T-DM1 or trastuzumab for 14 cycles.

Adjuvant therapy with trastuzumab emtansine has shown improved outcomes. New research findings are summarized in a short video.